MDS Expanded Dx (UK) at Chughtai Lab

MDS Expanded Dx (UK) at Chughtai Lab

Myelodysplastic Syndromes (MDS) represent a complex group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, progressive peripheral cytopenias, and a variable risk of transformation into Acute Myeloid Leukemia (AML). Accurate diagnosis and risk stratification are paramount for optimizing clinical management. The MDS Expanded Dx (UK) at Chughtai Lab is a state-of-the-art molecular diagnostic panel designed to perform comprehensive genomic profiling of patients suspected of having or diagnosed with MDS. This advanced panel utilizes Next-Generation Sequencing (NGS) technology to detect somatic mutations across a highly curated set of genes known to drive myeloid malignancies. By aligning with international diagnostic standards, including reference frameworks from the United Kingdom, this test provides clinicians with critical genomic insights that morphology alone cannot reveal.

The clinical utility of the MDS Expanded Dx (UK) panel extends across the entire patient care pathway. In the diagnostic phase, it helps differentiate clonal disorders from reactive causes of cytopenia, such as nutritional deficiencies, autoimmune diseases, or drug-induced bone marrow suppression. In the prognostic phase, the identification of specific genetic mutations allows for precise risk-scoring using the Molecular International Prognostic Scoring System (IPSS-M). This genomic risk-stratification is vital for determining whether a patient requires immediate aggressive therapy, such as an allogeneic hematopoietic stem cell transplant, or can be managed with conservative supportive care. Furthermore, the panel identifies actionable mutations that can guide targeted therapeutic interventions, ensuring a highly personalized approach to patient care at Chughtai Lab.

Clinical Procedure: What to Expect

The MDS Expanded Dx (UK) at Chughtai Lab is a highly specialized molecular test that requires careful sample collection, handling, and processing to ensure the integrity of the genetic material. Understanding the clinical procedure helps patients feel prepared and comfortable.

Patient Preparation

To ensure accurate results and a smooth testing process, patients should follow these preparation guidelines:

• No Fasting Required: There is generally no need to fast before this test. Patients can eat and drink normally unless instructed otherwise by their physician.
• Medical History Documentation: It is highly recommended to provide copies of recent Complete Blood Count (CBC) reports, bone marrow aspirate/biopsy findings, and clinical history. This information is invaluable to the hematopathologist interpreting the genomic data.
• Medication Disclosure: Inform the collection staff of all current medications, especially blood thinners or chemotherapy agents, as they may impact sample collection or clinical correlation.
• Hydration: Staying well-hydrated is beneficial, particularly if a peripheral blood sample is being collected, as it makes venipuncture easier.

During the Procedure

The sample collection process is straightforward and adheres to strict clinical protocols:

• Sample Type: The test can be performed using either a peripheral blood sample or a bone marrow aspirate sample, depending on the physician’s request and clinical context.
• Peripheral Blood Collection: If peripheral blood is used, a trained phlebotomist will clean the skin over a vein in your arm with an antiseptic. A sterile needle will be inserted to draw blood into a specialized EDTA tube. The process takes only a few minutes and involves minimal discomfort.
• Bone Marrow Aspirate Collection: If bone marrow is required, the procedure is performed by a qualified hematologist in a clinical setting. Local anesthesia is applied to the hip bone area, and a specialized needle is used to extract a small amount of liquid bone marrow. Patients may feel a brief pressure or pulling sensation.
• Sample Transport: Once collected, the sample is carefully labeled with unique patient identifiers and transported under strict temperature-controlled conditions to Chughtai Lab’s advanced molecular diagnostics division to preserve DNA and RNA integrity.
• Safety and Comfort: All procedures are conducted using sterile, single-use equipment to eliminate any risk of infection. Our staff is trained to ensure patient comfort throughout the process.

When is an MDS Expanded Dx (UK) Performed?

The clinical decision to order the MDS Expanded Dx (UK) panel at Chughtai Lab is guided by specific clinical presentations, hematological findings, and diagnostic challenges. Below are the primary clinical indications for this advanced molecular evaluation:

Unexplained Persistent Cytopenias

When a patient presents with persistent cytopenia (such as unexplained anemia, neutropenia, or thrombocytopenia) lasting for six months or longer, and standard clinical investigations fail to identify a clear etiology (such as nutritional deficiencies, autoimmune disorders, or drug-induced suppression), molecular profiling is indicated. The MDS Expanded Dx (UK) panel helps differentiate clonal cytopenias, such as Clonal Cytopenia of Undetermined Significance (CCUS), from non-clonal reactive cytopenias, providing a definitive diagnostic pathway.

Suspected Myelodysplastic Syndrome (MDS)

In patients where morphological evaluation of the bone marrow aspirate and biopsy shows borderline or equivocal dysplastic features, confirming a diagnosis of MDS can be challenging. The detection of somatic mutations with a variant allele frequency (VAF) of 2% or higher in myeloid-associated genes provides strong evidence of clonal hematopoiesis. This molecular confirmation is crucial for establishing a definitive diagnosis of MDS in morphologically ambiguous cases.

Prognostic Stratification and Risk Scoring

Once a diagnosis of MDS is established, determining the patient’s prognostic risk is essential for planning treatment. Traditional scoring systems like the IPSS-R rely solely on clinical and cytogenetic parameters. The MDS Expanded Dx (UK) panel provides the genomic data required for the Molecular International Prognostic Scoring System (IPSS-M). This advanced risk-stratification tool integrates mutations in 31 genes to predict overall survival and leukemia-free survival with significantly greater accuracy.

Monitoring Clonal Evolution and Disease Progression

Myelodysplastic Syndromes are dynamic clonal disorders that can evolve over time. Clinicians request this panel when there is a sudden change in the patient’s clinical status, such as worsening cytopenias, an increase in bone marrow blast count, or loss of response to therapy. Performing the MDS Expanded Dx (UK) panel allows hematologists to detect clonal evolution, such as the acquisition of high-risk mutations like TP53 or RUNX1, which signal rapid progression toward acute myeloid leukemia.

Selection of Targeted Therapeutic Options

The therapeutic landscape for MDS is increasingly guided by the patient’s genomic profile. For example, patients with SF3B1 mutations may benefit from luspatercept, while those with IDH1 or IDH2 mutations may be candidates for targeted inhibitors. Additionally, identifying TP53 mutations helps clinicians decide whether to proceed rapidly to allogeneic hematopoietic stem cell transplantation, as these patients often have poor responses to standard hypomethylating agents alone.

What Does an MDS Expanded Dx (UK) Detect?

The MDS Expanded Dx (UK) panel utilizes high-throughput Next-Generation Sequencing to detect somatic mutations, insertions, deletions, and copy number variations across key genes. The clinical significance of these detections includes:

• SF3B1 Mutation: Indicates a high likelihood of Myelodysplastic Syndrome with ring sideroblasts (MDS-RS), generally associated with a more favorable prognosis and potential response to luspatercept.
• TP53 Mutation: Detects alterations in the tumor suppressor gene, which are strongly associated with complex karyotypes, therapy-related MDS, resistance to standard therapies, and high risk of leukemic transformation.
• ASXL1 Mutation: Identifies mutations in this epigenetic regulator, which serve as an independent adverse prognostic marker associated with shorter overall survival.
• TET2 Mutation: Detects mutations in the ten-eleven translocation 2 gene, a common early clonal event in myeloid malignancies that may influence response to hypomethylating agents.
• DNMT3A Mutation: Identifies DNA methyltransferase alterations, which are key drivers of clonal hematopoiesis of indeterminate potential (CHIP) and early myeloid oncogenesis.
• RUNX1 Mutation: Detects mutations in this critical transcription factor, which are associated with severe thrombocytopenia, advanced disease stages, and rapid progression to AML.
• SRSF2 Mutation: Identifies splicing factor mutations that are highly prevalent in chronic myelomonocytic leukemia (CMML) and are associated with worse clinical outcomes in classic MDS.
• U2AF1 Mutation: Detects mutations in the U2 small nuclear RNA auxiliary factor 1 gene, which are associated with severe cytopenias and an increased risk of progression to acute leukemia.
• ZRSR2 Mutation: Identifies mutations in this minor spliceosome component, often associated with specific morphologic features and myelomonocytic differentiation.
• JAK2 V617F Mutation: Detects the classic JAK2 mutation, helping differentiate MDS from myeloproliferative neoplasms (MPN) or identifying MDS/MPN overlap syndromes.
• CALR Mutation: Identifies calreticulin gene mutations, which are valuable in evaluating patients presenting with thrombocytosis or suspected overlap syndromes.
• MPL Mutation: Detects myeloproliferative leukemia virus oncogene mutations, assisting in the comprehensive evaluation of clonal myeloid disorders.
• IDH1 Mutation: Identifies isocitrate dehydrogenase 1 mutations, which represent targetable molecular alterations in patients with advanced myeloid malignancies.
• IDH2 Mutation: Identifies isocitrate dehydrogenase 2 mutations, providing prognostic information and identifying eligibility for targeted therapeutic inhibitors.
• EZH2 Mutation: Detects mutations in the enhancer of zeste homolog 2 gene, which are associated with poor overall survival and rapid disease progression.
• CBL Mutation: Identifies mutations in the Casitas B-lineage lymphoma gene, commonly associated with CMML and myeloproliferative features.
• ETV6 Mutation: Detects mutations in this transcription factor, which are associated with cytopenias and adverse prognostic risk.
• SETBP1 Mutation: Identifies mutations associated with atypical chronic myeloid leukemia and rapid clonal evolution.
• BCOR Mutation: Detects BCL6 corepressor mutations, which are associated with bone marrow failure syndromes and poor prognosis in MDS.
• BCORL1 Mutation: Identifies mutations in the BCOR-like 1 gene, which serve as markers of clonal myeloid disease.
• STAG2 Mutation: Detects cohesin complex mutations, which are associated with chromosomal instability and adverse clinical outcomes.
• RAD21 Mutation: Identifies mutations in the cohesin complex, contributing to the understanding of clonal evolution in MDS.
• SMC3 Mutation: Detects structural maintenance of chromosomes 3 mutations, indicating genetic instability.
• PPM1D Mutation: Identifies mutations associated with therapy-related MDS, particularly in patients with prior exposure to cytotoxic chemotherapy.
• PHF6 Mutation: Detects mutations in the PHD finger protein 6 gene, which are associated with advanced disease stages and lineage plasticity.

Turnaround Time and Report Access at Chughtai Lab

Due to the highly complex nature of Next-Generation Sequencing (NGS) and the meticulous bioinformatic analysis required for the MDS Expanded Dx (UK) panel, the turnaround time is typically longer than standard blood tests. Chughtai Lab is committed to delivering accurate results as efficiently as possible, with reports generally finalized within two to three weeks. Once the analysis is complete, the genomic data is reviewed and signed off by a consultant hematopathologist.

Patients and their referring physicians can easily access the diagnostic reports through Chughtai Lab’s secure online portal or the official Chughtai Lab mobile application. Additionally, reports can be collected directly from any Chughtai Lab diagnostic center or delivered via email. This seamless digital access ensures that clinicians can promptly review the genomic findings and initiate personalized treatment plans without unnecessary delays.

MDS Expanded Dx (UK) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
SF3B1 Gene	Wild-type (No mutation detected)	Somatic mutation detected; associated with ring sideroblasts and favorable prognosis.
TP53 Gene	Wild-type (No mutation detected)	Somatic mutation detected; associated with complex karyotype, therapy-related MDS, and adverse prognosis.
ASXL1 Gene	Wild-type (No mutation detected)	Somatic mutation detected; associated with epigenetic dysregulation and poor prognosis.
TET2 Gene	Wild-type (No mutation detected)	Somatic mutation detected; common epigenetic driver, may correlate with hypomethylating agent response.
RUNX1 Gene	Wild-type (No mutation detected)	Somatic mutation detected; associated with advanced disease and increased risk of AML transformation.
SRSF2 Gene	Wild-type (No mutation detected)	Somatic mutation detected; splicing factor alteration associated with chronic myelomonocytic leukemia (CMML) features.
IDH1 / IDH2 Genes	Wild-type (No mutation detected)	Somatic mutation detected; represents potential therapeutic targets for IDH inhibitors.
DNMT3A Gene	Wild-type (No mutation detected)	Somatic mutation detected; associated with clonal hematopoiesis and variable clinical outcomes.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for MDS Expanded Dx (UK)?

• Experienced healthcare professionals: Our team of highly qualified hematopathologists and molecular biologists ensures the highest standards of diagnostic accuracy.
• Patient-focused care: We prioritize patient comfort and clarity throughout the diagnostic journey, providing comprehensive support.
• Quality diagnostic services: Chughtai Lab is committed to maintaining international quality standards across all molecular and genetic testing procedures.
• Professional reporting: Our diagnostic reports are detailed, structured, and designed to provide clear, actionable insights for clinical decision-making.
• Modern diagnostic approach: We utilize advanced Next-Generation Sequencing (NGS) platforms to deliver precise genomic profiling.
• Comfortable environment: Our state-of-the-art collection centers across Pakistan offer a clean, safe, and welcoming environment for patients.
• Convenient location: With a vast network of diagnostic centers and home sample collection services, accessing advanced diagnostics is simple and hassle-free.
• Commitment to accurate diagnosis: Since 1983, Chughtai Lab has been Pakistan’s trusted partner in pathology, delivering reliable results that clinicians trust.